iShares Biotechnology ETF
764 hedge funds and large institutions have $7.8B invested in iShares Biotechnology ETF in 2020 Q2 according to their latest regulatory filings, with 160 funds opening new positions, 258 increasing their positions, 198 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
15% more funds holding
Funds holding: 667 → 764 (+97)
4.19% more ownership
Funds ownership: 79.69% → 83.88% (+4.2%)
16% less call options, than puts
Call options by funds: $615M | Put options by funds: $736M
Holders
764
Holding in Top 10
24
Calls
$615M
Puts
$736M
Top Buyers
| 1 | +$315M | |
| 2 | +$253M | |
| 3 | +$217M | |
| 4 |
CM
Churchill Management
Los Angeles,
California
|
+$213M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$85.2M |
Top Sellers
| 1 | -$169M | |
| 2 | -$120M | |
| 3 | -$63.1M | |
| 4 |
Morgan Stanley
New York
|
-$47.8M |
| 5 |
Millennium Management
New York
|
-$31.9M |